BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sensus Healthcare Announces the Publication of a Comprehensive Study on Treating Non-Melanoma Skin Cancer in American Academy of Dermatology


10/1/2012 12:16:41 PM

BOCA RATON, Fla., Sept. 28, 2012 /PRNewswire/ -- SensusHealthcare is pleased to announce the acceptance and publication of the most comprehensive study to date on treating Non Melanoma Skin Cancer (NMSC) with superficial radiotherapy (SRT) in the Journal of the American Academy of Dermatology (JAAD). The comprehensive study, which examined 1,715 NMSC lesions in 1,149 patients, dubbed "Superficial x-ray in the treatment of basal and squamous cell carcinomas", was authored by Dr. Armand Cognetta and his colleagues. The study finds that SRT is a viable and effective modality in the physician's toolbox to successfully treat NMSC patients with high cure rates and is complimentary to surgery and other treatment methods.

"The acceptance and publication of this study by the AAD society is very important and timely, considering the contemporary clinical and economic landscape, where there is an ongoing endeavor to employ sound and cost-effective methods to treat patients non-invasively, which will essentially lower the burden on the healthcare system and the economy in general, while maximizing clinical outcomes, cure rates, and overall patient quality of life. The SRT-100 is in the sweet spot of addressing the challenges our society is coping with nowadays, while offering the patients and physicians excellent results. We are proud to be on the forefront of providing a treatment solution that is truly beneficial to everyone involved in this equation the patients, physicians, and the healthcare system," stated Joe Sardano, President/CEO, Sensus Healthcare.

About Sensus Healthcare:
Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100 systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings. SRT-100 is an ideal treatment modality for non-melanoma skin cancers, thanks to its SharpBeam characteristics, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100 is FDA, CE, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards.

Media Contact:
Michelle Verina
Public Relations
561-922-5808 Ext. 100
michelle@sensushealthcare.com

SOURCE Sensus Healthcare



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES